JEIL PHARMA HOLDINGS INC. Statistics
Want to see KR:002620 full AI Analyst Report?
JEIL PHARMA HOLDINGS INC. (002620) Stock Statistics & Valuation Metrics
Total Valuation
JEIL PHARMA HOLDINGS INC. has a market cap or net worth of KRW 104.39B. The enterprise value is KRW 350.14B.
- Market Cap
- KRW 104.39B
- Enterprise Value
- KRW 350.14B
Share Statistics
JEIL PHARMA HOLDINGS INC. has 15,973,355 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 15,973,355
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
JEIL PHARMA HOLDINGS INC.’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 1.88%.
- Return on Equity (ROE)
- 0.05
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 1.88%
- Return on Capital Employed (ROCE)
- 0.03
- Revenue Per Employee
- 16.44B
- Profits Per Employee
- 365.88M
- Employee Count
- 40
- Asset Turnover
- 0.75
- Inventory Turnover
- 3.43
Valuation Ratios
The current PE Ratio of JEIL PHARMA HOLDINGS INC. is 12.37. JEIL PHARMA HOLDINGS INC.’s PEG ratio is 0.18.
- PE Ratio
- 12.37
- PS Ratio
- 0.17
- PB Ratio
- 0.33
- Price to FCF
- -56.29
- Price to Operating Cash Flow
- 8.80
- PEG Ratio
- 0.18
Income Statement
In the last 12 months, JEIL PHARMA HOLDINGS INC. had revenue of 657.61B and earned 14.64B in profits. Earnings per share was 953.37.
- Revenue
- 657.61B
- Gross Profit
- 226.27B
- Operating Income
- 15.07B
- Pretax Income
- 39.55B
- Net Income
- 14.64B
- EBITDA
- 30.02B
- Earnings Per Share (EPS)
- 953.37
Cash Flow
In the last 12 months, operating cash flow was 11.86B and capital expenditures -13.72B, giving a free cash flow of -1.85B billion.
- Operating Cash Flow
- 11.86B
- Free Cash Flow
- -1.85B
- Free Cash Flow per Share
- -120.80
Dividends & Yields
JEIL PHARMA HOLDINGS INC. pays an annual dividend of ―, resulting in a dividend yield of 1.03%
- Dividend Per Share
- ―
- Dividend Yield
- 1.03%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.78%
- Earnings Yield
- 8.08%
Stock Price Statistics
- Beta
- 0.07
- 52-Week Price Change
- -13.27%
- 50-Day Moving Average
- 7299.80
- 200-Day Moving Average
- 7749.75
- Relative Strength Index (RSI)
- 42.05
- Average Volume (3m)
- 4,653
Important Dates
JEIL PHARMA HOLDINGS INC. upcoming earnings date is Mar 17, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Mar 17, 2027
- Ex-Dividend Date
- ―
Financial Position
JEIL PHARMA HOLDINGS INC. as a current ratio of 1.16, with Debt / Equity ratio of 52.51%
- Current Ratio
- 1.16
- Quick Ratio
- 0.79
- Debt to Market Cap
- 1.30
- Net Debt to EBITDA
- 3.70
- Interest Coverage Ratio
- 2.01
Taxes
In the past 12 months, JEIL PHARMA HOLDINGS INC. has paid 4.72B in taxes.
- Income Tax
- 4.72B
- Effective Tax Rate
- 0.12
Enterprise Valuation
JEIL PHARMA HOLDINGS INC. EV to EBITDA ratio is -5.77, with an EV/FCF ratio of -122.11.
- EV to Sales
- 0.36
- EV to EBITDA
- -5.77
- EV to Free Cash Flow
- -122.11
- EV to Operating Cash Flow
- 19.09
Balance Sheet
JEIL PHARMA HOLDINGS INC. has KRW 87.50B in cash and marketable securities with KRW 184.74B in debt, giving a net cash position of -KRW 97.23B billion.
- Cash & Marketable Securities
- KRW 87.50B
- Total Debt
- KRW 184.74B
- Net Cash
- -KRW 97.23B
- Net Cash Per Share
- -KRW 6,087.25
- Tangible Book Value Per Share
- KRW 29.66K
Margins
Gross margin is 39.48%, with operating margin of -0.67%, and net profit margin of 1.35%.
- Gross Margin
- 39.48%
- Operating Margin
- -0.67%
- Pretax Margin
- 3.96%
- Net Profit Margin
- 1.35%
- EBITDA Margin
- -6.30%
- EBIT Margin
- 2.03%
Analyst Forecast
The average price target for JEIL PHARMA HOLDINGS INC. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -10.88%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 51

